Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico

C Gama; JM Benita; J Celaya

doi:10.1016/j.jval.2017.08.2915

Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico

Value in Health ◽

10.1016/j.jval.2017.08.2915 ◽

2017 ◽

Vol 20 (9) ◽

pp. A931

Author(s):

C Gama ◽

JM Benita ◽

J Celaya

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

The Public ◽

Effectiveness Analysis ◽

Genotype 1B ◽

Payer Perspective ◽

Public Payer

Download Full-text

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Cost Effectiveness and Resource Allocation ◽

10.1186/1478-7547-11-25 ◽

2013 ◽

Vol 11 (1) ◽

pp. 25 ◽

Cited By ~ 8

Author(s):

Fabio MR Barros ◽

Hugo Cheinquer ◽

Carolina T Tsuchiya ◽

Eduardo AV Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

Peginterferon Alfa

Download Full-text

PGI17 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)72336-6 ◽

2010 ◽

Vol 13 (3) ◽

pp. A71-A72 ◽

Cited By ~ 1

Author(s):

FMR Barros ◽

H Cheinquer ◽

LG Borges ◽

E Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

Peginterferon Alfa

Download Full-text

PGI18 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPE I CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)72337-8 ◽

2010 ◽

Vol 13 (3) ◽

pp. A72

Author(s):

FMR Barros ◽

H Cheinquer ◽

LG Borges ◽

E Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype I ◽

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

Peginterferon Alfa

Download Full-text

The Cost-Effectiveness Analysis of Elbasvir/Grazoprevir Versus Peginterferon Αlpha-2A in Combination with Ribavirin in Patients with Chronic Hepatitis C Genotype 1b Infection in China

Value in Health ◽

10.1016/j.jval.2018.07.486 ◽

2018 ◽

Vol 21 ◽

pp. S65

Author(s):

PY Chen ◽

Q Liu ◽

HC Li ◽

AX Ma

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Genotype 1B ◽

The Cost

Download Full-text

PGI19 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)72338-x ◽

2010 ◽

Vol 13 (3) ◽

pp. A72

Author(s):

FMR Barros ◽

H Cheinquer ◽

LG Borges ◽

E Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Peginterferon Alfa ◽

Private Payer

Download Full-text

Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1586/14737167.2015.1081061 ◽

2015 ◽

Vol 16 (2) ◽

pp. 285-294 ◽

Cited By ~ 9

Author(s):

Vicente Gimeno-Ballester ◽

Javier Mar ◽

Ramón San Miguel

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Genotype 1B

Download Full-text

PGI18 Treatment of Chronic Hepatitis C Patients with Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

Value in Health ◽

10.1016/j.jval.2011.08.889 ◽

2011 ◽

Vol 14 (7) ◽

pp. A394-A395

Author(s):

J. Areias ◽

T. Branco ◽

F. Calinas ◽

A. Carvalho ◽

G. Macedo ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Peginterferon Alfa ◽

Chronic Hepatitis C Patients

Download Full-text

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options

Journal of Viral Hepatitis ◽

10.1111/jvh.12278 ◽

2014 ◽

Vol 22 (2) ◽

pp. 175-183 ◽

Cited By ~ 14

Author(s):

P. A. Cortesi ◽

A. Ciaccio ◽

M. Rota ◽

J. K. Lim ◽

S. De Salvia ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Options ◽

Cost Effectiveness Analysis ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve

Download Full-text

Cost-Effectiveness Analysis Of Daclatasvir With Asunaprevir In Treatment Of Chronic Hepatitis C In The Russian Federation

Value in Health ◽

10.1016/j.jval.2016.09.397 ◽

2016 ◽

Vol 19 (7) ◽

pp. A415

Author(s):

R Yagudina ◽

A Kulikov ◽

VV Babiy

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Russian Federation ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

The Russian Federation

Download Full-text

PIN42 Cost-Effectiveness-Analysis of the Combination- Therapy Telaprevir, Peg-IFNα2a and Ribavirin in Patients With Chronic Hepatitis-C in Austria

Value in Health ◽

10.1016/j.jval.2012.08.1109 ◽

2012 ◽

Vol 15 (7) ◽

pp. A392

Author(s):

M. Said ◽

A. Dragosits ◽

E. Walter

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text